Nadine H. Abdallah, M.D.

  1. Borges GA, Diaz-delCastillo M, Guilatco AJ, El-Masri BM, Mustapha FA, Gundesen MT, Hinge M, Lund T, Abdallah N, Baughn LB, Xu M, Gingery A, Tchkonia T, Kirkland JL, Kourelis T, Drake MT, Andersen TL, Weivoda MM. Senescence profiling of monoclonal gammopathies reveals paracrine senescence as a crucial defense against disease progression. Leukemia. 2025 May; 39 (5):1206-1217 Epub 2025 Mar 31
    View PubMed
  2. Bolarinwa A, Nagaraj M, Zanwar S, Abdallah N, Bergsagel PL, Binder M, Buadi F, Chhabra S, Cook J, Dingli D, Dispenzieri A, Gertz MA, Gonsalves W, Hayman S, Kapoor P, Kourelis T, Leung N, Lin Y, Muchtar E, Parrondo R, Roy V, Sher T, Siddiqui M, Warsame R, Fonder A, Hobbs M, Hwa YL, Rogers M, Yadav U, Wiedmeier-Nutor JE, Baughn LB, Vincent Rajkumar S, Fonseca R, Ailawadhi S, Kumar S. Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes. Blood Cancer J. 2025 Apr 4; 15 (1):57 Epub 2025 Apr 04
    View PubMed
  3. Abdallah N, Dizona P, Kumar A, LaPlant B, Menser T, Schaeferle G, Aug S, Weivoda M, Dispenzieri A, Buadi FK, Warsame R, Cook J, Lacy MQ, Hayman S, Gertz MA, Rajkumar SV, Kumar SK. Cumulative deficits frailty index and relationship status predict survival in multiple myeloma. Blood Adv. 2025 Mar 11; 9 (5):1137-1146
    View PubMed
  4. Abdallah N, Bohra A, Mammadzadeh A, Buadi F, Kapoor P, Dispenzieri A, Gertz M, Hayman S, ElHaj M, Dingli D, Cook J, Binder M, Lin Y, Kourelis T, Warsame R, Thompson C, Menser T, Rajkumar SV, Kumar S. Prognostic impact of patient-reported symptoms in multiple myeloma. Blood Adv. 2025 Feb 25; 9(4):884-892.
    View PubMed
  5. Zanwar S, Jevremovic D, Kapoor P, Olteanu H, Buadi F, Horna P, Gonsalves W, Otteson G, Bolarinwa AB, Hayman S, Abdallah N, Binder M, Cook J, Dispenzieri A, Dingli D, Gertz MA, Kourelis T, Leung N, Lin Y, Muchtar E, Warsame R, Fonder A, Hobbs M, Hwa YL, Rogers M, Kyle RA, Rajkumar SV, Kumar S. Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myeloma. Blood Cancer J. 2025 Feb 18; 15 (1):20
    View PubMed
  6. Abdallah N, Kumar SK. Up-Front Treatment of Elderly (Age >/=75 Years) and Frail Patients With Multiple Myeloma. J Natl Compr Canc Netw. 2024 Nov; 22 (9)
    View PubMed
  7. Abdallah N, Murray D, Dispenzieri A, Kapoor P, Gertz MA, Lacy MQ, Hayman SR, Buadi FK, Gonsalves W, Muchtar E, Leung N, Dingli D, Kourelis T, Warsame R, Binder M, Kyle RA, Rajkumar SV, Kumar S. Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. Leukemia. 2024 Aug; 38 (8):1864
    View PubMed
  8. Lipof JJ, Abdallah N, Lipe B. Personalized Treatment of Multiple Myeloma in Frail Patients. Curr Oncol Rep. 2024 Jul; 26 (7):744-753 Epub 2024 May 18
    View PubMed
  9. Abdallah N, Witzig TE, Kumar SK, Lacy MQ, Hayman SR, Dispenzieri A, Roy V, Gertz MA, Bergsagel PL, Rajkumar SV. Phase III randomized trial of Thal+ZLD versus ZLD in patients with asymptomatic multiple myeloma - updated results after 18-year follow-up. Leukemia. 2024 May; 38 (5):1169-1171 Epub 2024 Feb 28
    View PubMed
  10. Abdallah N, Kumar SK. New Therapies on the Horizon for Relapsed Refractory Multiple Myeloma. Hematol Oncol Clin North Am. 2024 Apr; 38 (2):511-532 Epub 2024 Jan 11
    View PubMed
  11. Begna KH, Abdallah NH, Janania-Martinez M, Mangaonkar AA, Rangan A, Herrick JL, Gangat N. Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant. Haematologica. 2024 Feb 1; 109 (2):689-692 Epub 2024 Feb 01
    View PubMed
  12. Abdallah NH, Lakshman A, Kumar SK, Cook J, Binder M, Kapoor P, Dispenzieri A, Gertz MA, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Lin Y, Kourelis T, Warsame R, Bergsagel L, Rajkumar SV. Mode of progression in smoldering multiple myeloma: a study of 406 patients. Blood Cancer J. 2024 Jan 17; 14 (1):9
    View PubMed
  13. Rees M, Abdallah N, Yohannan B, Gonsalves WI. Bispecific antibody targets and therapies in multiple myeloma. Front Immunol. 2024; 15:1424925 Epub 2024 Oct 10
    View PubMed
  14. Abdallah NH, Nagayama H, Takahashi N, Gonsalves W, Fonder A, Dispenzieri A, Dingli D, Buadi FK, Lacy MQ, Hobbs M, Gertz MA, Binder M, Kapoor P, Warsame R, Hayman SR, Kourelis T, Hwa YL, Lin Y, Kyle RA, Rajkumar SV, Broski SM, Kumar SK. Muscle and fat composition in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2023 Dec 12; 13 (1):185
    View PubMed
  15. Abdallah N, Dispenzieri A, Muchtar E, Buadi FK, Kapoor P, Lacy MQ, Hwa YL, Fonder A, Hobbs MA, Hayman SR, Leung N, Dingli D, Go RS, Lin Y, Gonsalves WI, Binder M, Kourelis T, Warsame R, Kyle RA, Rajkumar SV, Gertz MA, Kumar SK. The impact of Post-Transplant doxycycline in AL amyloidosis - updated results after Long-Term follow up. Amyloid. 2023 Sep; 30 (3):261-267 Epub 2022 Dec 19
    View PubMed
  16. Abdallah NH, Smith AN, Geyer S, Binder M, Greipp PT, Kapoor P, Dispenzieri A, Gertz MA, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Hwa YL, Lin Y, Kourelis T, Warsame R, Kyle RA, Rajkumar SV, Kumar SK. Conditional survival in multiple myeloma and impact of prognostic factors over time. Blood Cancer J. 2023 May 15; 13 (1):78
    View PubMed
  17. Abdallah N, Purrington KS, Tatineni S, Assad H, Petrucelli N, Simon MS. Racial and ethnic variation in BRCA1 and BRCA2 genetic test results among individuals referred for genetic counseling at a large urban comprehensive cancer center. Cancer Causes Control. 2023 Feb; 34 (2):141-149 Epub 2022 Nov 12
    View PubMed
  18. Nandakumar B, Baffour F, Abdallah NH, Kumar SK, Dispenzieri A, Buadi FK, Dingli D, Lacy MQ, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Muchtar E, Warsame R, Kourelis TV, Go RS, Kyle RA, Gertz MA, Rajkumar SV, Klug J, Korfiatis P, Gonsalves WI. Sarcopenia identified by computed tomography imaging using a deep learning-based segmentation approach impacts survival in patients with newly diagnosed multiple myeloma. Cancer. 2023 Feb 1; 129 (3):385-392 Epub 2022 Nov 22
    View PubMed
  19. Abdallah N, Murray D, Dispenzieri A, Kapoor P, Gertz MA, Lacy MQ, Hayman SR, Buadi FK, Gonsalves W, Muchtar E, Leung N, Dingli D, Kourelis T, Warsame R, Binder M, Kyle RA, Rajkumar SV, Kumar S. Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. Leukemia. 2022 May; 36 (5):1449
    View PubMed
  20. Abdallah N, Murray D, Dispenzieri A, Kapoor P, Gertz MA, Lacy MQ, Hayman SR, Buadi FK, Gonsalves W, Muchtar E, Leung N, Dingli D, Kourelis T, Warsame R, Binder M, Kyle RA, Rajkumar SV, Kumar S. Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab. Leukemia 2022 May; 36 (5):1426-1428 Epub 2022 Jan 29
    View PubMed
  21. Abdallah NH, Habermann T, Buadi FK, Gertz MA, Lacy MQ, Rajkumar SV, Dingli D, Go RS, Hayman SR, Kumar SK, Kourelis T, Warsame R, Kapoor P, Muchtar E, Hwa YL, Fonder AL, Hobbs MA, Lin Y, Leung N, Binder M, Siddiqui MA, Kyle RA, Witzig TE, Dispenzieri A. Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. Am J Hematol. 2022 Apr; 97(4):401-410. Epub 2022 Jan 19.
    View PubMed
  22. Tatineni S, Tarockoff M, Abdallah N, Purrington KS, Assad H, Reagle R, Petrucelli N, Simon MS. Racial and ethnic variation in multigene panel testing in a cohort of BRCA1/2-negative individuals who had genetic testing in a large urban comprehensive cancer center. Cancer Med. 2022 Mar; 11 (6):1465-1473 Epub 2022 Jan 17
    View PubMed
  23. Abdallah NH, Binder M, Rajkumar SV, Greipp PT, Kapoor P, Dispenzieri A, Gertz MA, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder AL, Hobbs MA, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui MA, Kyle RA, Bergsagel PL, Fonseca R, Ketterling RP, Kumar SK. A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer J. 2022 Jan 31; 12 (1):21
    View PubMed
  24. Sharma N, Smadbeck JB, Abdallah N, Zepeda-Mendoza C, Binder M, Pearce KE, Asmann YW, Peterson JF, Ketterling RP, Greipp PT, Bergsagel PL, Rajkumar SV, Kumar SK, Baughn LB. The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma. Clin Cancer Res. 2021 Oct 1; 27 (19):5430-5439
    View PubMed
  25. Xie Z, Saliba AN, Abeykoon J, Majeed U, Almquist DR, Wiedmeier-Nutor JE, Bezerra E, Andrade-Gonzalez X, Hickman A, Sorenson K, Rakshit S, Wee C, Tella SH, Kommalapati A, Abdallah N, Pritchett J, De Andrade M, Uprety D, Badley A, Manochakian R, Ailawadhi S, Bryce AH, Hubbard JM, Gangat N, Thompson CA, Witzig TE, McWilliams RR, Leventakos K, Halfdanarson TR. Outcomes of COVID-19 in Patients With Cancer: A Closer Look at Pre-Emptive Routine Screening Strategies. JCO Oncol Pract. 2021 Sep; 17 (9):e1382-e1393 Epub 2021 June 14
    View PubMed
  26. Abdallah N, Dispenzieri A, Muchtar E, Buadi FK, Kapoor P, Lacy MQ, Hwa YL, Fonder A, Hobbs MA, Hayman SR, Leung N, Dingli D, Lust JA, Go RS, Lin Y, Gonsalves WI, Kourelis T, Warsame R, Kyle RA, Rajkumar SV, Gertz MA, Kumar SK. Prognostic restaging after treatment initiation in patients with AL amyloidosis. Blood Adv. 2021 Feb 23; 5 (4):1029-1036
    View PubMed
  27. Abdallah N, Muchtar E, Dispenzieri A, Gonsalves W, Buadi F, Lacy MQ, Hayman SR, Kourelis T, Kapoor P, Go RS, Warsame R, Leung N, Rajkumar SV, Kyle RA, Pruthi RK, Gertz MA, Kumar SK. Coagulation Abnormalities in Light Chain Amyloidosis. Mayo Clin Proc. 2021 Feb; 96 (2):377-387
    View PubMed
  28. Kanj A, Samhouri B, Abdallah N, Chehab O, Baqir M. Host Factors and Outcomes in Hospitalizations for Pneumocystis Jirovecii Pneumonia in the United States. Mayo Clin Proc. 2021 Feb; 96 (2):400-407
    View PubMed
  29. Abdallah N, Baughn LB, Rajkumar SV, Kapoor P, Gertz MA, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui M, Lust J, Kyle RA, Ketterling R, Bergsagel L, Greipp P, Kumar SK. Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. Clin Cancer Res. 2020 Dec 15; 26 (24):6581-6588 Epub 2020 Oct 02
    View PubMed
  30. Abdallah N, Greipp P, Kapoor P, Gertz MA, Dispenzieri A, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui M, Lust J, Kyle RA, Bergsagel L, Ketterling R, Rajkumar SV, Kumar SK. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Adv. 2020 Aug 11; 4 (15):3509-3519
    View PubMed
  31. Abdallah N, Rajkumar SV, Greipp P, Kapoor P, Gertz MA, Dispenzieri A, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui M, Lust J, Kyle RA, Bergsagel L, Ketterling R, Kumar SK. Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. Blood Cancer J. 2020 Aug 11; 10 (8):82
    View PubMed
  32. Abdallah N, Kim S, Ayash L, Klimecki S, Ventimiglia M, Alavi A, Ratanatharathorn V, Uberti J, Deol A. Does use of biosimilar G-CSF change plerixafor utilization during stem cell mobilization for autologous stem cell transplant? Bone Marrow Transplant 2020 Aug; 55 (8):1655-1657 Epub 2019 Nov 18
    View PubMed
  33. Abdallah N, Sidana S, Dispenzieri A, Lacy M, Buadi F, Hayman S, Kapoor P, Leung N, Dingli D, Hwa YL, Lust J, Russell S, Gonsalves W, Go R, Hogan W, Kyle R, Rajkumar SV, Gertz M, Kumar S. Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. Bone Marrow Transplant. 2020 Jul; 55 (7):1297-1304 Epub 2020 June 09
    View PubMed
  34. Abdallah N, Kapoor P, Murray DL, Buadi FK, Dingli D, Dispenzieri A, Gertz MA, Go RS, Gonsalves WI, Hayman SR, Kourelis TV, Lacy MQ, Leung N, Lust JA, Muchtar E, Warsame R, Kyle RA, Rajkumar SV, Kumar SK. Utility of serum free light chain ratio in response definition in patients with multiple myeloma. Blood Adv. 2020 Jan 28; 4 (2):322-326
    View PubMed
  35. Chehab O, Abdallah N, Kanj A, Pahuja M, Adegbala O, Morsi RZ, Mishra T, Afonso L, Abidov A. Impact of immune thrombocytopenic purpura on clinical outcomes in patients with acute myocardial infarction. Clin Cardiol. 2019 Nov 11 [Epub ahead of print]
    View PubMed
  36. Mohamed A, Twardy B, AbdAllah N, Akhras A, Ismail H, Zordok M, Schrapp K, Attumi T, Tesfaye A, El-Rayes B. Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results. J Gastrointest Cancer. 2019 Jun; 50 (2):269-275
    View PubMed
  37. Sukari A, Abdallah N, Nagasaka M. Unleash the power of the mighty T cells-basis of adoptive cellular therapy. Crit Rev Oncol Hematol. 2019 Apr; 136:1-12 Epub 2019 Jan 25
    View PubMed
  38. Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Grogan M, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Chakraborty R, Gonsalves W, Kourelis TV, Warsame R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA. Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. Amyloid. 2019; 26(sup1):101-102.
    View PubMed
  39. Abdallah N, Kumar SK. Daratumumab in untreated newly diagnosed multiple myeloma. Ther Adv Hematol. 2019; 10:2040620719894871 Epub 2019 Dec 23
    View PubMed
  40. Nagasaka M, Abdallah N, Crosby M, Thummala N, Patel D, Wozniak AJ, Gadgeel S, Abrams J, Sukari A. A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors. Lung Cancer (Auckl). 2019; 10:95-105 Epub 2019 Sept 12
    View PubMed
  41. Kanj A, Abdallah N, Soubani AO. The spectrum of pulmonary aspergillosis. Respir Med. 2018 Aug; 141:121-131 Epub 2018 July 03
    View PubMed
  42. Nagasaka M, Abdallah N, Samantray J, Sukari A. Is this really just "fatigue"? A case series of immune-related central adrenal insufficiency secondary to immune checkpoint inhibitors. Clin Case Rep. 2018 Jul; 6 (7):1278-1281 Epub 2018 May 24
    View PubMed
  43. Abdallah N, Nagasaka M, Abdulfatah E, Shi D, Wozniak AJ, Sukari A. Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation. Lung Cancer (Auckl). 2018; 9:85-90 Epub 2018 Oct 25
    View PubMed